arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Stereotaxis, Inc.

STXS Health Care Biotechnology: Electromedical & Electrotherapeutic Apparatus
$1.40
▲ +0.0% Today
as of Sep 4, 16:55 ET
Last 30 days +6.92% Jul 27 → Sep 04
$1.24 $1.30 $1.37 $1.43 $1.49 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$1.38
High
$1.41
Low
$1.38
Volume
$344,298
Avg Vol
$571,679
Mkt Cap
$138M
P/E (TTM)
—
Beta
—
52w High
$3.59
52w Low
$1.24
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 10 items

Aug 18 · 22:44 Motley Fool
Stereotaxis (STXS) Q2 2026 Earnings Call Transcript
Aug 12 · 12:30 Moby
Stereotaxis, Inc. Q2 2026 Earnings Call Summary
Aug 12 · 03:04 MarketBeat
Stereotaxis Q2 Earnings Call Highlights
▸ Show all 10 press releases & news Free account →

Overview

52-week range
$1.24
$3.59
7% of range
Avg surprise (last 3)
+17.9%
Avg reaction (last 2)
-0.3%
50% positive
Latest IV / EM
898%
EM ±140.3% · $3 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.58$-0.32$-0.06$0.21$0.47 Actual $-0.07Actual $-0.07Actual $-0.07Actual $-0.06Actual $-0.07Actual $-0.08Actual $-0.07Est $-0.07Actual $-0.05Est $-0.07Actual $-0.07Actual $-0.03Est $-0.04Actual $-0.05 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-6M$-2M$2M$6M$10M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.05 — — — — financials
Tue May 12, 2026Mar/2026 $-0.03 $-0.04 +25.0% +57.1% +2.1% earnings
Tue Sep 30, 2025Sep 2025 $-0.07 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.05 $-0.07 +28.6% — — earnings
Mon May 12, 2025Mar/2025 $-0.07 $-0.07 0.0% — -2.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.08 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.07 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.06 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.07 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.07 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.07 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$8M$6M—$7M$9M$7M—$9M
Cost of revenue$3M$2M—$3M$4M$3M—$5M
Gross profit$4M$4M—$4M$5M$4M—$4M
Operating income$-5M$-6M—$-7M$-4M$-6M—$-6M
Net income$-4M$-6M—$-6M$-4M$-6M—$-6M
EPS (diluted)$-0.05$-0.06—$-0.07$-0.05$-0.07—$-0.08

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$10M$15M$13M$11M$7M$11M$12M$11M
Inventory$13M$10M$10M$10M$10M$10M$8M$9M
Total current assets$38M$36M$34M$27M$22M$26M$26M$29M
Total assets$56M$54M$52M$46M$41M$46M$47M$51M
Long-term debt————————
Total liabilities$38M$34M$34M$34M$34M$38M$35M$35M
Total equity$12M$14M$13M$6M$1M$3M$6M$11M

Implied volatility — last 90 days

243%1221%2200%3178%4157% Jun 08 — IV 628% · EM ±82.9%Jun 09 — IV 582% · EM ±73.0%Jun 10 — IV 585% · EM ±69.1%Jun 11 — IV 622% · EM ±68.7%Jun 12 — IV 558% · EM ±57.1%Jun 15 — IV 939% · EM ±67.9%Jun 16 — IV 1256% · EM ±74.2%Jun 17 — IV 1682% · EM ±70.2%Jun 19 — IV 325% · EM ±71.8%Jun 22 — IV 243% · EM ±50.8%Jun 23 — IV 254% · EM ±51.9%Jun 24 — IV 398% · EM ±79.8%Jun 25 — IV 520% · EM ±101.9%Jun 26 — IV 422% · EM ±80.8%Jun 29 — IV 538% · EM ±95.4%Jun 30 — IV 456% · EM ±78.5%Jul 01 — IV 389% · EM ±65.0%Jul 02 — IV 397% · EM ±64.2%Jul 03 — IV 411% · EM ±64.2%Jul 06 — IV 458% · EM ±63.5%Jul 07 — IV 458% · EM ±60.4%Jul 08 — IV 510% · EM ±63.9%Jul 09 — IV 580% · EM ±68.6%Jul 10 — IV 794% · EM ±87.7%Jul 13 — IV 1205% · EM ±100.6%Jul 14 — IV 1469% · EM ±106.2%Jul 15 — IV 1515% · EM ±89.5%Jul 16 — IV 2608% · EM ±108.9%Jul 20 — IV 543% · EM ±128.4%Jul 21 — IV 578% · EM ±134.4%Jul 22 — IV 628% · EM ±143.7%Jul 23 — IV 653% · EM ±146.9%Jul 24 — IV 842% · EM ±186.0%Jul 27 — IV 846% · EM ±176.7%Jul 28 — IV 802% · EM ±164.1%Jul 29 — IV 826% · EM ±165.4%Jul 30 — IV 838% · EM ±164.1%Jul 31 — IV 1016% · EM ±194.4%Aug 03 — IV 1084% · EM ±192.1%Aug 04 — IV 838% · EM ±144.2%Aug 05 — IV 840% · EM ±140.3%Aug 06 — IV 864% · EM ±139.7%Aug 07 — IV 1014% · EM ±158.5%Aug 10 — IV 1078% · EM ±149.3%Aug 11 — IV 1179% · EM ±155.8%Aug 12 — IV 1257% · EM ±157.5%Aug 13 — IV 1359% · EM ±160.6%Aug 14 — IV 1422% · EM ±157.1%Aug 17 — IV 1881% · EM ±157.1%Aug 18 — IV 2287% · EM ±165.4%Aug 19 — IV 2638% · EM ±155.8%Aug 20 — IV 4157% · EM ±173.6%Aug 24 — IV 705% · EM ±147.3%Aug 25 — IV 763% · EM ±156.0%Aug 26 — IV 654% · EM ±131.0%Aug 27 — IV 712% · EM ±139.5%Aug 28 — IV 739% · EM ±141.4%Aug 31 — IV 803% · EM ±142.4%Sep 01 — IV 911% · EM ±156.9%Sep 02 — IV 1000% · EM ±167.1%Sep 03 — IV 867% · EM ±140.3%Sep 04 — IV 898% · EM ±140.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in